CASE.EDU:    HOME | DIRECTORIES | SEARCH
case western reserve university

THE LANDRETH LAB

 

Laboratory Publications

GARY LANDRETH, Ph.D.

Landreth Lab Publications (since 2010)

Wilkinson, B, Cramer, P, Varvel, N, Reed-Geaghan, E, Jiang, Q., Szabo, A., Herrup, K.,, Lamb, B. and Landreth, G. Ibuprofen attenuates oxidative damage through inhibition of microglial NOX2 in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Aging 33:197, e21-32, 2010. PMID: 20696495

Gamboa J, Blankenship D, Niemi JP, Landreth GE, Karl M, Hilow E, Sundararajan S. Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. Neuroscience170:-846-857, 2010. PMID: 20691766

Reed-Geaghan, EG, Savage, JC, Hise, AG, Landreth, GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar Abeta-stimulated microglial activation. J Neurosci. 29:11982-92, 2009. PMID: 19776284

Geldmacher, D., Fritsch, McClendon, M.J. and Landreth, G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer’s disease. Arch Neurol. 68:45-50, 2010. PMID: 20837824

Reed-Geaghan, E., Geaghan, Q., Cramer, P., and Landreth, G. Deletion of CD14 attenuates AD pathology by influencing the brain’s inflammatory milieu. J. Neurosci. 30:15369-15373, 2010.

Fyffe-Maricich SL, Karlo JC, Landreth GE, Miller RH. The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J Neurosci. 31:843-50, 2011. PMID: 21248107

Newbern JM, Li X, Shoemaker SE, Zhou J, Zhong J, Wu Y, Bonder D, Hollenback S, Coppola G, Specific functions for ERK/MAPK signaling during PNS development. Geschwind DH, Landreth GE, Snider WD. Neuron. 69:91-105, 2011 PMID: 21220101

Lee, C.Y., Tse, W. and Landreth, G. Apoe E promotes Ab trafficking and degradation by modulating microglial cholesterol levels. J. Biol. Chem. 287:2032-44, 2011. PMID: 22130662

Wesson DW, Borkowski AH, Landreth GE, Nixon RA, Levy E, Wilson DA. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer’s ß-amyloidosis mouse model. J. Neurosci. 31:15692-15671, 2011 PMID:22049439

Cramer, PE., Cirrito, JR., Wesson, DW, Lee, C, Karlo, JC, Zinn, AE., Casali, BT, Restivo, JL, Goebel, WD ,. James, MJ, Brunden, KR, Wilson, DA and Landreth, GE. ApoE-directed Therapeutics Rapidly Clear ß-amyloid and Reverse Deficits in AD Mouse Models. Science 335:1503-1506, 2012. PMID: 22323736

Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-Gamma-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer’s Disease. J Neurosci. 32:10117-28, 2012. PMID: 22836247

Pucilowska J, Puzerey PA, Karlo JC, Galán RF, Landreth GE. Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facial-cutaneous and related syndromes. J Neurosci. 32:8663-77, 2012. PMID:22723706

Cameron, BD, Tse, W, Lamb, R, Li, X, Lamb, BT and Landreth, GE. Loss of Interleukin Receptor Associated Kinase 4 Signaling Suppresses Amyloid Pathology and Alters Microglial Phenotype in a Mouse Model of Alzheimer’s Disease. J. Neurosci. 32:15112-151123, 2012. PMID: 23100432

Grommes C, Karlo JC, Caprariello A, Blankenship D, Dechant A, Landreth GE. The PPARg agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemother Pharmacol. 71:929-36, 2013. PMID: 23358645

Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 19:13-18. 2013. PMID 23601557

Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA.

Response to comments on “ApoE-directed therapeutics rapidly clear ß-amyloid and reverse deficits in AD mouse models”. Science. 2013;340:924-926, 2013. PMID: 23704556

Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J. Bexarotene reduces network excitability in models of Alzheimer’s disease and epilepsy. Neurobiol Aging. 35:2091-5, 2014. PMID:24767949

Lee, S., Xu, G., Jay, T., Bhatta, S., Kim, K.W., Jung, S., Landreth, G., Ransohoff, R and Lamb, B. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J. Neurosci. 34:12538-12546, 2014 PMID: 25209291

Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE. Activation of the nuclear receptor PPARg is neuroprotective in a transgenic mouse model of Alzheimer’s disease through inhibition of inflammation. J Neuroinflammation. 12:1-7, 2015. PMID 25592770

Pucilowska, J., Vithayathil, J., Tavares, E., Kelly, C., Karlo J. and Landreth, G. The 16p11.2 Deletion Mouse Model of Autism Exhibits Altered Cortical Progenitor Proliferation and Brain Cytoarchitecture Linked to the ERK MAPK Pathway. J. Neurosci. 35:3190-3200, 2015.

Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer ‘s disease mouse models. J Exp Med. 212:287-295, 2015 PMID: 25732305

Savage, JC, Jay, T., Goduni, E., Quigley, C., Mariani, M., Malm, T., Ransohoff, R., Lamb, BT and Landreth, GE. Nuclear receptors license phagocytosis in TREM2+ myleloid cells in mouse models of Alzheimer’s disease. J. Neurosci. 35:6532-6543, 2015.PMID 25904803

Vithaytahil, J., Pucilowska, J., Goodnough,, LH., Atit, R. and GE Landreth. . Dentate gyrus development requires ERK activity to maintain progenitor population and MAPK pathway feedback regulation. J. Neurosci. 35:6836-6848, 2015 PMID: 25926459.

Casali, B., Corona, A., Mariaqni, M., Karlo, J, Ghosal, K and GE Landreth. Omega-3 fatty acids augment the actions of nuclear receptor agonists in a mouse model of Alzheimer’s disease. J. Neurosci. 35:9173-9181, 2015. PMID: 26085639

Corona AW, Kodoma N, Casali BT, Landreth GE. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. J Neuroimmune Pharmacol. 2015 Jul 15. PMID: 26175148

Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE. Combined Liver X Receptor/Peroxisome Proliferator-Activated Receptor Gamma Agonist Treatment Reduces Amyloid-ß Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J. Biol. Chem. 2015 Jul 10. pii: jbc.M115.652008. PMID: 26163517

 

Reviews

Cameron, B. and G. Landreth. Inflammation, microglia and Alzheimer’s disease. Neurobiol. Dis. Neurobiol. Dis. 37:503-509, 2010. PMID: 19833208

Mandrekar-Colucci, S. and G. Landreth. Microglia and inflammation in Alzheimer’s Disease. CNS Neurol. Disord. Drug Targets 9:157-167, 2010.

Lee, C.Y. and G. Landreth. The role of microglia in amyloid clearance from the AD brain. J. Neural Trans. 117:949-960, 2010. PMID: 20552234

Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer’s disease. Expert Opin Ther Targets. 9:1085-1097, 2011 PMID: 21718217

Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE. Evidence for impaired amyloid ß clearance in Alzheimer’s disease. Alzheimers Res Ther. 2013 5:33, 2013 PMID: 23849219

Skerrett R, Malm T, Landreth G. Nuclear receptors in neurodegenerative diseases. Neurobiol Dis. Epub, 2014. doi: 10.1016/j.nbd.2014.05.019. PMID: 24874548.

Malm TM, Jay TR, Landreth GE. The Evolving Biology of Microglia in Alzheimer’s Disease. Neurotherapeutics. 12:81-93, 2015. PMID 25404051